Changsheng Ye

No.1838 North Guangzhou Avenue
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 11, 2025

Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.

Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.

Journal: Clinical drug investigation

Published: December 24, 2024

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 20, 2024

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

Journal: BMJ (Clinical research ed.)

Published: October 31, 2023

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.

Journal: BMC cancer

Published: March 29, 2023

Sauchinone inhibits breast cancer cell proliferation through regulating microRNA-148a-3p/HER-2 axis.

Sauchinone inhibits breast cancer cell proliferation through regulating microRNA-148a-3p/HER-2 axis.

Journal: Thoracic cancer

Published: November 16, 2022

Host-guest complexation of cyclophosphamide by carboxylatopillar[6]arene for increasing stability and enhancing its curative effect on breast carcinoma.

Host-guest complexation of cyclophosphamide by carboxylatopillar[6]arene for increasing stability and enhancing its curative effect on breast carcinoma.

Journal: Bioorganic & medicinal chemistry letters

Published: September 07, 2022

A genomic and transcriptomic study toward breast cancer.

A genomic and transcriptomic study toward breast cancer.

Journal: Frontiers in genetics

Published: July 08, 2022

Prevalence of breast fibroadenoma in healthy physical examination population in Guangdong province of China: a cross-sectional study.

Prevalence of breast fibroadenoma in healthy physical examination population in Guangdong province of China: a cross-sectional study.

Journal: BMJ open

Published: June 27, 2022

HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer.

HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer.

Journal: Frontiers in oncology

Published: December 07, 2021

Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.

Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.

Journal: Future oncology (London, England)

Published: October 25, 2021

Integrated analyses of long noncoding RNAs and mRNAs in the progression of breast cancer.

Integrated analyses of long noncoding RNAs and mRNAs in the progression of breast cancer.

Journal: The Journal of international medical research

Published: September 16, 2021

Showing 1-12 of 44

Last Updated: 09/26/2026